Advertisement
Screener

GSK plc (GLAXF) Form 6-K: Report of foreign private issuer, 2022, Page 2

2.1 / 5 stars · 17/40 Roast Me

Add as a preferred source on Google

GSK plc Form 6-K: Report of foreign private issuer

Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.

  • 2022-05-19: Form 6-K; Period of report 2022-05-19; Description IAIN MACKAY - EXTERNAL APPOINTMENT; Document a1088m.htm.
  • 2022-05-16: Form 6-K; Period of report 2022-05-16; Description CHANGE OF NAME TO GSK PLC; Document a6487l.htm.
  • 2022-05-13: Form 6-K; Period of report 2022-05-13; Description DIRECTOR/PDMR SHAREHOLDING; Document a5143l.htm.
  • 2022-05-12: Form 6-K; Period of report 2022-05-12; Description DIRECTOR/PDMR SHAREHOLDING; Document a2524l.htm.
FiledFormPeriod of reportDescriptionDocument
2022-05-196-K2022-05-19IAIN MACKAY - EXTERNAL APPOINTMENTa1088m.htm
2022-05-166-K2022-05-16CHANGE OF NAME TO GSK PLCa6487l.htm
2022-05-136-K2022-05-13DIRECTOR/PDMR SHAREHOLDINGa5143l.htm
2022-05-126-K2022-05-12DIRECTOR/PDMR SHAREHOLDINGa2524l.htm
2022-05-116-K2022-05-11BLOCK LISTING INTERIM REVIEWa1732l.htm
2022-05-096-K2022-05-09DIRECTOR/PDMR SHAREHOLDINGa8232k.htm
2022-05-046-K2022-05-04RESULT OF AGMa3634k.htm
2022-05-046-K2022-05-04DIRECTORATE CHANGEa2672k.htm
2022-05-036-K2022-05-03TOTAL VOTING RIGHTSa1739k.htm
2022-04-276-K2022-04-271ST QUARTER RESULTSq12022_26aprilfinalrns.htm
2022-04-266-K2022-04-26DIRECTOR/PDMR SHAREHOLDINGa3600j.htm
2022-04-196-K2022-04-19DAPRODUSTAT APPLICATION ACCEPTED FOR REVIEW BY FDAa5070i.htm
2022-04-146-K2022-04-14DIRECTOR/PDMR SHAREHOLDINGa4551i.htm
2022-04-146-K2022-04-14DIRECTOR/PDMR SHAREHOLDINGa4543i.htm
2022-04-146-K2022-04-14DIRECTOR/PDMR SHAREHOLDINGa4501i.htm
2022-04-136-K2022-04-13DIRECTOR/PDMR SHAREHOLDINGa3276i.htm
2022-04-136-K2022-04-13DIRECTOR/PDMR SHAREHOLDINGa2630i.htm
2022-04-136-K2022-04-13GSK AGREES TO ACQUIRE SIERRA ONCOLOGY FOR $1.9BNa2409i.htm
2022-04-126-K2022-04-12DIRECTOR/PDMR SHAREHOLDINGa1770i.htm
2022-04-126-K2022-04-12DIRECTOR/PDMR SHAREHOLDINGa1687i.htm
2022-04-126-K2022-04-12DIRECTOR/PDMR SHAREHOLDINGa1669i.htm
2022-04-126-K2022-04-12DIRECTOR/PDMR SHAREHOLDINGa1661i.htm
2022-04-016-K2022-04-01TOTAL VOTING RIGHTSa0284h.htm
2022-04-016-K2022-04-01GSK - SEGMENT AND PRODUCT SALES REPORTING CHANGESa9694g.htm
2022-03-286-K2022-03-28PUBLICATION OF 2022 AGM NOTICEa2616g.htm
2022-03-246-K2022-03-24DIRECTOR/PDMR SHAREHOLDINGa9581f.htm
2022-03-246-K2022-03-24FDA UPDATE: CABENUVA ORAL LEAD-IN NOW OPTIONALa9412f.htm
2022-03-236-K2022-03-23DIRECTOR/PDMR SHAREHOLDINGa8150f.htm
2022-03-236-K2022-03-23ISSUANCE OF NOTESa6788f.htm
2022-03-166-K2022-03-16DIRECTOR/PDMR SHAREHOLDINGa0255f.htm
2022-03-156-K2022-03-15DIRECTOR/PDMR SHAREHOLDINGa8673e.htm
2022-03-156-K2022-03-15APPOINTMENTS TO DESIGNATE HALEON BOARDa8170e.htm
2022-03-116-K2022-03-11DIRECTOR/PDMR SHAREHOLDINGa5490e.htm
2022-03-096-K2022-03-09DIRECTOR/PDMR SHAREHOLDINGa2215e.htm
2022-03-086-K2022-03-08GSK ANNUAL REPORT 2021 ON FORM 20-Fa1014e.htm
2022-03-046-K2022-03-04GSK PUBLISHES ANNUAL REPORT 2021a7015d.htm
2022-03-016-K2022-03-01TOTAL VOTING RIGHTSa2422d.htm
2022-03-016-K2022-03-01DIRECTOR/PDMR SHAREHOLDINGa2243d.htm
2022-03-016-K2022-03-01DIRECTOR/PDMR SHAREHOLDINGa1851d.htm
2022-03-016-K2022-03-01DAPRODUSTAT APPLICATION ACCEPTED FOR REVIEW BY EMAa1058d.htm
2022-02-286-K2022-02-28FOMR 6-Kglaxo_6k.htm
2022-02-286-K2022-02-28FORM 6-Kglaxf_6k.htm
2022-02-246-K2022-02-24DIRECTOR/PDMR SHAREHOLDINGa7639c.htm
2022-02-246-K2022-02-24CANADA APPROVAL FOR MEDICAGO GSK COVID-19 VACCINEa7594c.htm
2022-02-236-K2022-02-23DIRECTOR/PDMR SHAREHOLDINGa6084c.htm
2022-02-226-K2022-02-22DIRECTOR/PDMR SHAREHOLDINGa4245c.htm
2022-02-226-K2022-02-22GSK CONSUMER HEALTHCARE TO BE CALLED HALEONa4582c.htm
2022-02-186-K2022-02-18DIRECTOR/PDMR SHAREHOLDINGa1857c.htm
2022-02-186-K2022-02-18GSK GIVES UPDATE ON RSV MATERNAL VACCINE CANDIDATEa0662c.htm
2022-02-176-K2022-02-17DIRECTOR/PDMR SHAREHOLDINGa0503c.htm
2022-02-176-K2022-02-17DIRECTOR/PDMR SHAREHOLDINGa0488c.htm
2022-02-176-K2022-02-17DIRECTOR/PDMR SHAREHOLDINGa0458c.htm
2022-02-176-K2022-02-17DIRECTOR/PDMR SHAREHOLDINGa0454c.htm
2022-02-176-K2022-02-17DIRECTOR/PDMR SHAREHOLDINGa0449c.htm
2022-02-166-K2022-02-16DIRECTOR/PDMR SHAREHOLDINGa9237b.htm
2022-02-146-K2022-02-14DIRECTOR/PDMR SHAREHOLDINGa6487b.htm
2022-02-146-K2022-02-14TRANSFER OF TREASURY SHARESa6221b.htm
2022-02-116-K2022-02-11DIRECTOR/PDMR SHAREHOLDINGa4815b.htm
2022-02-116-K2022-02-11DIRECTOR/PDMR SHAREHOLDINGa4412b.htm
2022-02-106-K2022-02-10BENLYSTA APPROVED IN CHINA FOR LUPUS NEPHRITISa2840b.htm
2022-02-096-K2022-02-09FINAL RESULTSa0848b1gskoriginal.htm
2022-02-096-K2022-02-09DIRECTOR/PDMR SHAREHOLDINGa1785b.htm
2022-02-076-K2022-02-07PUBLICATION OF FULL YEAR 2021 RESULTSa8778a.htm
2022-02-026-K2022-02-02GSK ANNOUNCES SETTLEMENT BETWEEN VIIV AND GILEADa3934a.htm
2022-02-016-K2022-02-01FDA APPROVES VIIV HEALTHCARE'S SNDA FOR CABENUVAa3523a.htm
2022-02-016-K2022-02-01TOTAL VOTING RIGHTSa3394a.htm
2022-01-266-K2022-01-26DIRECTOR/PDMR SHAREHOLDINGa7570z.htm
2022-01-206-K2022-01-20DIRECTOR/PDMR SHAREHOLDINGa1453z.htm
2022-01-196-K2022-01-19DIRECTOR/PDMR SHAREHOLDINGa0022z.htm
2022-01-196-K2022-01-19DIRECTOR/PDMR SHAREHOLDINGa9966y.htm
2022-01-196-K2022-01-19DIRECTOR/PDMR SHAREHOLDINGa9961y.htm
2022-01-196-K2022-01-19TONY WOOD APPOINTED CSO DESIGNATE, GSKa9332y.htm
2022-01-186-K2022-01-18DIRECTOR/PDMR SHAREHOLDINGa7267y.htm
2022-01-186-K2022-01-18DIRECTOR/PDMR SHAREHOLDINGa7138y.htm
2022-01-186-K2022-01-18UPDATE - GSK CONSUMER HEALTHCAREa5952y.htm
2022-01-146-K2022-01-14DIRECTOR/PDMR SHAREHOLDINGa5330y.htm
2022-01-136-K2022-01-13DIRECTOR/PDMR SHAREHOLDINGa4011y.htm
2022-01-116-K2022-01-11DIRECTOR/PDMR SHAREHOLDINGa1196y.htm
2022-01-116-K2022-01-11US GOVT BUYS ADDITIONAL 600,000 SOTROVIMAB DOSESa1017y.htm
2022-01-046-K2022-01-04TOTAL VOTING RIGHTSa3802x.htm
Advertisement